Enhanced diltiazem bioavailability after oral administration of diltiazem with quercetin to rabbits

被引:46
作者
Choi, JS [1 ]
Li, XG
机构
[1] Chosun Univ, Coll Pharm, Kwangju 501759, South Korea
[2] Yanbian Univ, Coll Nursing, Jilin 133000, Peoples R China
关键词
diltiazem; quercetin; bioavailability; co-administration; pretreatment;
D O I
10.1016/j.ijpharm.2004.12.004
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The aim of this study was to investigate the effect of quercetin on the bioavailability of diltiazem after administering diltiazem (15 mg/kg) orally to rabbits either co-administered or pretreated with quercetin (2, 10, 20 mg/kg). The plasma concentrations of diltiazem in the rabbits pretreated with quercetin were increased significantly (p < 0.05, at 2 mg/kg; p < 0.01, at 10 and 20 mg/kg) compared with the control, but the plasma concentrations of diltiazem co-administered with quercetin were not significant. The areas under the plasma concentration-time curve (AUC) and the peak concentrations (C-max) of the diltiazem in the rabbits pretreated with quercetin were significantly higher (p < 0.05, at 2 mg/kg; p < 0.01, at 10 and 20 mg/kg) than the control. The absolute bioavailability (AB%) of diltiazem in the rabbits pretreated with quercetin was significantly (p < 0.05 at 2 mg/kg, p < 0.01 at 10 and 20 mg/kg) higher (9.10-12.81%) than the control (4.64%). AUC, AB% and C-max of diltiazem co-administered with quercetin were higher than the control, but these were not significant. The bioavailibility of diltiazem in the rabbits pretreated with quercetin is increased significantly compared with the control, but not in the rabbits co-administered with quercetin. The increased bioavailability of diltiazem in the rabbits pretreated with quercetin might have been resulted result from the quercetin, which inhibits the efflux pump P-glycoprotein and the first-pass metabolizing enzyme CYP 3A4. (c) 2005 Elsevier B.V. All rights reserved.
引用
收藏
页码:1 / 8
页数:8
相关论文
共 39 条
[1]  
Bardelmeijer HA, 2000, CLIN CANCER RES, V6, P4416
[2]   DILTIAZEM - A REAPPRAISAL OF ITS PHARMACOLOGICAL PROPERTIES AND THERAPEUTIC USE [J].
BUCKLEY, MMT ;
GRANT, SM ;
GOA, KL ;
MCTAVISH, D ;
SORKIN, EM .
DRUGS, 1990, 39 (05) :757-806
[3]   DILTIAZEM - A REVIEW OF ITS PHARMACOLOGICAL PROPERTIES AND THERAPEUTIC EFFICACY [J].
CHAFFMAN, M ;
BROGDEN, RN .
DRUGS, 1985, 29 (05) :387-454
[4]   MULTIDRUG-RESISTANCE GENE (P-GLYCOPROTEIN) IS EXPRESSED BY ENDOTHELIAL-CELLS AT BLOOD-BRAIN BARRIER SITES [J].
CORDONCARDO, C ;
OBRIEN, JP ;
CASALS, D ;
RITTMANGRAUER, L ;
BIEDLER, JL ;
MELAMED, MR ;
BERTINO, JR .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1989, 86 (02) :695-698
[5]   Flavonoids and isoflavonoids - a gold mine for metabolic engineering [J].
Dixon, RA ;
Steele, CL .
TRENDS IN PLANT SCIENCE, 1999, 4 (10) :394-400
[6]   Bioflavonoids: selective substrates and inhibitors for cytochrome P450CYP1A and CYP1B1 [J].
Doostdar, H ;
Burke, MD ;
Mayer, RT .
TOXICOLOGY, 2000, 144 (1-3) :31-38
[7]   Enhancement of moxidectin bioavailability in lamb by a natural flavonoid: quercetin [J].
Dupuy, J ;
Larrieu, G ;
Sutra, JF ;
Lespine, A ;
Alvinerie, M .
VETERINARY PARASITOLOGY, 2003, 112 (04) :337-347
[8]  
Gan LSL, 1996, DRUG METAB DISPOS, V24, P344
[9]   HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHIC DETERMINATION OF DILTIAZEM AND 4 OF ITS METABOLITES IN PLASMA - APPLICATION TO PHARMACOKINETICS [J].
GOEBEL, KJ ;
KOLLE, EU .
JOURNAL OF CHROMATOGRAPHY, 1985, 345 (02) :355-363
[10]   BIOCHEMISTRY OF MULTIDRUG-RESISTANCE MEDIATED BY THE MULTIDRUG TRANSPORTER [J].
GOTTESMAN, MM ;
PASTAN, I .
ANNUAL REVIEW OF BIOCHEMISTRY, 1993, 62 :385-427